Dermira Inc. (NASDAQ:DERM)’s share price was up 2% on Monday . The stock traded as high as $32.78 and last traded at $32.63, with a volume of 79,001 shares traded. The stock had previously closed at $32.00.

Several equities analysts have recently weighed in on DERM shares. Needham & Company LLC reiterated a “buy” rating and issued a $46.00 target price on shares of Dermira in a research note on Wednesday, June 22nd. Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a research note on Wednesday, June 22nd. Wedbush lifted their target price on shares of Dermira from $42.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 2nd. Finally, Leerink Swann reiterated a “buy” rating and issued a $46.00 target price (up previously from $39.00) on shares of Dermira in a research note on Tuesday, May 10th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $41.00.

The stock’s market capitalization is $1.23 billion. The company’s 50-day moving average price is $31.65 and its 200-day moving average price is $27.13.

Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.86) by $0.03. Equities research analysts predict that Dermira Inc. will post ($3.39) EPS for the current fiscal year.

In other Dermira news, VP Christopher M. Griffith sold 1,303 shares of the company’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $31.75, for a total transaction of $41,370.25. Following the transaction, the vice president now owns 44,941 shares in the company, valued at approximately $1,426,876.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Thomas G. Wiggans sold 11,000 shares of the company’s stock in a transaction dated Wednesday, June 1st. The shares were sold at an average price of $31.57, for a total transaction of $347,270.00. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Dermira stock. Jennison Associates LLC increased its stake in shares of Dermira Inc. (NASDAQ:DERM) by 8.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,097,201 shares of the biopharmaceutical company’s stock after buying an additional 83,858 shares during the period. Jennison Associates LLC owned approximately 3.67% of Dermira worth $37,974,000 at the end of the most recent quarter.

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.